BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 25878115)

  • 21. Evolution of recombinant lymphocytic choriomeningitis virus/Lassa virus in vivo highlights the importance of the GPC cytosolic tail in viral fitness.
    Sommerstein R; Ramos da Palma J; Olschläger S; Bergthaler A; Barba L; Lee BP; Pasquato A; Flatz L
    J Virol; 2014 Aug; 88(15):8340-8. PubMed ID: 24829355
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural killer T cell immunotherapy combined with oncolytic vesicular stomatitis virus or reovirus treatments differentially increases survival in mouse models of ovarian and breast cancer metastasis.
    Gebremeskel S; Nelson A; Walker B; Oliphant T; Lobert L; Mahoney D; Johnston B
    J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33722907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Attenuation of vesicular stomatitis virus infection of brain using antiviral drugs and an adeno-associated virus-interferon vector.
    Wollmann G; Paglino JC; Maloney PR; Ahmadi SA; van den Pol AN
    Virology; 2015 Jan; 475():1-14. PubMed ID: 25462341
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment.
    Koske I; Rössler A; Pipperger L; Petersson M; Barnstorf I; Kimpel J; Tripp CH; Stoitzner P; Bánki Z; von Laer D
    Int J Cancer; 2019 Oct; 145(7):1958-1969. PubMed ID: 30972741
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Highly attenuated recombinant vesicular stomatitis virus VSV-12'GFP displays immunogenic and oncolytic activity.
    van den Pol AN; Davis JN
    J Virol; 2013 Jan; 87(2):1019-34. PubMed ID: 23135719
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
    Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
    J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncolytic vesicular stomatitis virus in an immunocompetent model of MUC1-positive or MUC1-null pancreatic ductal adenocarcinoma.
    Hastie E; Besmer DM; Shah NR; Murphy AM; Moerdyk-Schauwecker M; Molestina C; Roy LD; Curry JM; Mukherjee P; Grdzelishvili VZ
    J Virol; 2013 Sep; 87(18):10283-94. PubMed ID: 23864625
    [TBL] [Abstract][Full Text] [Related]  

  • 28. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy.
    Wu L; Huang TG; Meseck M; Altomonte J; Ebert O; Shinozaki K; García-Sastre A; Fallon J; Mandeli J; Woo SL
    Hum Gene Ther; 2008 Jun; 19(6):635-47. PubMed ID: 18533893
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vesicular stomatitis virus expressing interferon-β is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer.
    Patel MR; Jacobson BA; Ji Y; Drees J; Tang S; Xiong K; Wang H; Prigge JE; Dash AS; Kratzke AK; Mesev E; Etchison R; Federspiel MJ; Russell SJ; Kratzke RA
    Oncotarget; 2015 Oct; 6(32):33165-77. PubMed ID: 26431376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer.
    Hastie E; Grdzelishvili VZ
    J Gen Virol; 2012 Dec; 93(Pt 12):2529-2545. PubMed ID: 23052398
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interference of CD40L-mediated tumor immunotherapy by oncolytic vesicular stomatitis virus.
    Galivo F; Diaz RM; Thanarajasingam U; Jevremovic D; Wongthida P; Thompson J; Kottke T; Barber GN; Melcher A; Vile RG
    Hum Gene Ther; 2010 Apr; 21(4):439-50. PubMed ID: 19922169
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Susceptibility of breast cancer cells to an oncolytic matrix (M) protein mutant of vesicular stomatitis virus.
    Ahmed M; Puckett S; Lyles DS
    Cancer Gene Ther; 2010 Dec; 17(12):883-92. PubMed ID: 20725101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Single-cycle viral gene expression, rather than progressive replication and oncolysis, is required for VSV therapy of B16 melanoma.
    Galivo F; Diaz RM; Wongthida P; Thompson J; Kottke T; Barber G; Melcher A; Vile R
    Gene Ther; 2010 Feb; 17(2):158-70. PubMed ID: 20016540
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors.
    Porosnicu M; Quinson AM; Crossley K; Luecke S; Lauer UM
    Future Oncol; 2022 Aug; 18(24):2627-2638. PubMed ID: 35699077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations in the glycoprotein of vesicular stomatitis virus affect cytopathogenicity: potential for oncolytic virotherapy.
    Janelle V; Brassard F; Lapierre P; Lamarre A; Poliquin L
    J Virol; 2011 Jul; 85(13):6513-20. PubMed ID: 21561919
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants.
    Pipperger L; Riepler L; Kimpel J; Siller A; Stoitzner P; Bánki Z; von Laer D
    Oncoimmunology; 2021; 10(1):1959140. PubMed ID: 34484872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Diversity in responses to oncolytic Lassa-vesicular stomatitis virus in patient-derived glioblastoma cells.
    Kim TE; Puckett S; Zhang K; Herpai DM; Ornelles DA; Davis JN; van den Pol AN; Debinski W; Lyles DS
    Mol Ther Oncolytics; 2021 Sep; 22():232-244. PubMed ID: 34514102
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.
    Wollmann G; Davis JN; Bosenberg MW; van den Pol AN
    J Virol; 2013 Jun; 87(12):6644-59. PubMed ID: 23552414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Variable deficiencies in the interferon response enhance susceptibility to vesicular stomatitis virus oncolytic actions in glioblastoma cells but not in normal human glial cells.
    Wollmann G; Robek MD; van den Pol AN
    J Virol; 2007 Feb; 81(3):1479-91. PubMed ID: 17108037
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.